Crescendo – Proprietary, robust, and highly efficient transgenic VH domain technology

The T cell enhancing company

Crescendo Biologics enters pre-clinical collaboration with Orano Med to explore Targeted Alpha Therapy 6 July 2020

Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic 5 May 2020

Crescendo Biologics appoints Dr Kenji Hashimoto as Chief Medical Officer 3 February 2020

Crescendo Biologics is focusing on novel T cell enhancing therapeutics in immuno-oncology.

Crescendo Biologics (Crescendo) is focused on transforming the lives of cancer patients through its pipeline of novel T cell enhancing therapies. The lead programme, CB307, is a first in class CD137 (4-1BB) x PSMA bispecific molecule. Behind the lead programme is a pipeline of other first or best in class CD137 (4-1BB) bispecifics for solid tumours.

T cell enhancing pipeline advantages:

Enhanced safety via conditional activation of tumour-specific T cells in the tumour micro-environment
Proliferation of tumour-specific T cells to enhance tumour cell killing
Survival of tumour-specific T cells for a more durable anti-cancer effect (‘memory’ responses)

Crescendo’s pipeline is underpinned by its proprietary Humabody® V_H platform. This platform is based on its transgenic mouse, from which are derived fully human V_H domains. These V_H domains can be used on their own or can be combined with other V_H domains to create multi-functional molecules with unique properties designed to overcome some of the limitations of traditional IgG-based molecules.